Streetbeat News

Products Services

SPCE

OceanGate Expedition's submersible vessel Titan went missing during a Titanic expedition, highlighting the extreme tourism industry. High-priced adventures include space tourism offered by Virgin Galactic Holdings Inc (NYSE:SPCE) and trips to the depths of the Mariana Trench by EYOS Expeditions.

Portfolio Pulse from AJ Fabino

June 22, 2023 | 6:59 pm

LLY

NVO

NVS

TERN

Mizuho initiated coverage on Terns Pharmaceuticals with a Buy rating and a price target of $16, implying a 35% upside. The analyst believes TERN-501 for NASH is the company's most de-risked asset and main driver of valuation. TERN-601 for obesity is considered Terns' hottest asset, while TERN-701 for chronic myeloid leukemia is the most underappreciated.

Portfolio Pulse from Vandana Singh

June 22, 2023 | 6:54 pm

SRPT

The FDA has granted accelerated approval to Sarepta Therapeutics' gene therapy, Elevidys, for Duchenne muscular dystrophy (DMD) in pediatric patients aged 4-5 years with a confirmed mutation in the DMD gene. Continued approval depends on further verification and description of clinical benefit in confirmatory trials. Sarepta is preparing to launch Elevidys and plans to submit a BLA supplement to expand the approved label based on the results of the confirmatory trial.

Portfolio Pulse from Vandana Singh

June 22, 2023 | 6:48 pm

EXAS

Exact Sciences Corporation (NASDAQ:EXAS) is poised to dominate the emerging precision oncology market, with a potential $18 billion market. Analysts reiterate Buy ratings and raise price targets, as the company's Cologuard test shows promising results and management remains confident in future growth prospects.

Portfolio Pulse from Nabaparna Bhattacharya

June 22, 2023 | 6:38 pm

MDB

MongoDB shares are trading higher after the company announced several new product launches, including the MongoDB AI Innovators Program, MongoDB Atlas for Industries, and five new products and features for MongoDB Atlas. A new partnership with Google Cloud was also announced.

Portfolio Pulse from Ryan Gustafson

June 22, 2023 | 6:38 pm

INM

InMed Pharmaceuticals announced that its Phase 2 clinical trial for INM-755 CBN cream, a treatment for symptoms related to epidermolysis bullosa, showed non-statistically significant results for non-wound itch.

Portfolio Pulse from Benzinga Newsdesk

June 22, 2023 | 6:25 pm

TSLA

Two camouflaged Tesla Cybertrucks were spotted in California, raising speculation about the potential start of production. Tesla aims to start production in summer 2023, with a ramp-up in the following year.

Portfolio Pulse from Benzinga EV Insights

June 22, 2023 | 6:15 pm

SRPT

Sarepta Therapeutics has received FDA approval for ELEVIDYS, the first gene therapy to treat Duchenne Muscular Dystrophy. The one-time treatment is approved for ambulatory pediatric patients aged 4-5 years. Sarepta will host a conference call on June 22 at 4:30 p.m. ET.

Portfolio Pulse from Benzinga Newsdesk

June 22, 2023 | 6:03 pm

CP

CSX

CPKC and CSX have announced a planned collaboration to develop additional hydrogen locomotives, aiming to reduce greenhouse gas emissions and improve fuel efficiency.

Portfolio Pulse from Benzinga Newsdesk

June 22, 2023 | 6:01 pm

LTCUSD

Litecoin (CRYPTO: LTC) is trading lower by 2.94% to $85.27 during Thursday's session, pulling back after recent strength in the price of Bitcoin following BlackRock's Bitcoin ETF application. The cryptocurrency market is experiencing an upswing driven by favorable developments, including the introduction of EDX Markets, supported by Charles Schwab, Fidelity, and Citadel Securities.

Portfolio Pulse from Henry Khederian

June 22, 2023 | 6:00 pm